BETASERON

LOE Approaching

interferon beta-1b

BLASUBCUTANEOUSVIALPriority Review
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
37

Mechanism of Action

(interferon beta-1b) in patients with multiple sclerosis is unknown.

Clinical Trials (5)

NCT04356339N/ACompleted

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Started Nov 2020
100 enrolled
Multiple Sclerosis
NCT03134573N/ACompleted

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Started Sep 2017
96 enrolled
Multiple Sclerosis
NCT02652091N/ACompleted

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Started Feb 2016
146 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT02486640N/ACompleted

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

Started Sep 2015
162 enrolled
Multiple Sclerosis
NCT02247310N/ACompleted

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Started Oct 2014
498 enrolled
Multiple Sclerosis, Relapsing Remitting